By collaborating with HiPro Biotechnology Co. Ltd, a Chinese company with state-of-the-art cGMP facility and experienced personnel for cGMP manufacturing, Virovek is proud to announce that it will provide services for large-scale cGMP manufacturing of AAV vectors through its spinoff company, Virovek, LLC. Please contact us for more information.
Virovek has developed the world’s most robust and efficient large-scale AAV vector production platform [US Patent No. 8,945,918 B2 (issued February 3, 2015)]. This production technology has been further developed to produce at normal levels of AAV vectors carrying toxic genes for cancer therapy [US Patent No. 9,175,312 B2 (issued November 3, 2015)].
There is no longer a bottleneck in AAV production whether the AAV carries a non-toxic or a toxic gene as a result of our proprietary technologies. Combining the multi-fold scientific development and processing advancements in the field of gene therapy with Virovek’s scalable AAV production system, using AAV as a therapeutic vehicle for a broad range of diseases is now a reality.
Please contact us for a non-exclusive licensing opportunity.
Virovek is an adeno-associated virus (AAV) production and protein expression services company. With our unique and proprietary technologies, we provide our customers with:
- Custom-made AAV vector production service from 1E+13vg scale to 3E+16vg scale. We have the world’s most powerful and efficient AAV vector production platform
- Toxin-based cell ablation technology using AAV vectors as the delivery vehicle. This is the world’s first and only AAV-toxin vector production platform
- Hard-to-refold protein expression and purification services using the bacterial expression system or the eukaryotic baculovirus expression system